# Why Combination Therapy Fails in Practice

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/why-combination-therapy-fails-in-practice

> A pragmatic trial of combining two diabetes drugs found 53% filled the prescription against 84% on one drug, and half of those who filled later stopped one. The participants were insured.

## Key points

- Fill rates at four months: 84% single drug, 53% combination.
- Of those who filled, 22% vs 49% discontinued, mostly for side effects.
- The participants were INSURED, with active support. These are better-than-average conditions.
- Third measurement in a row showing the gap between prescribed and taken is where the effect goes.

Guidelines increasingly suggest combining an SGLT2 inhibitor with a GLP-1 in type 2 diabetes. A pragmatic trial tried to test that in ordinary care and ran into something before it could measure any outcome: people did not fill the prescriptions. At four months, **84%** of the single-drug group had filled against **53%** of the combination group.[1]

## What happened

Participants were randomized to monotherapy or dual therapy and followed for a median of ten months. The gap in fill rates narrowed over time but did not close, ending at 87% against 68% overall. Among those who did fill, **22% of the monotherapy group and 49% of the dual therapy group discontinued a study medication**, mostly because of side effects.[1]

Half of the people who started two drugs stopped at least one of them. Quality-of-life scores showed no change in either group, which is unsurprising when so much of the intended treatment never happened.

> Among those who filled, 49% of the dual therapy group stopped a study medication, against 22% of the single-drug group.

## Why this population makes it worse, not better

The participants were **insured**, and the study team had actively worked to facilitate medication uptake during the feasibility phase.[1] These were not people who could not afford treatment, and the conditions were substantially better than average.

If half of an insured, supported, trial-enrolled population cannot sustain two drugs, the guideline describes a regimen that mostly does not survive contact with a pharmacy counter.

## It fits a pattern we keep finding

Three separate measurements now point the same way: a large share of the lost effect sits in the gap between what is prescribed and what is taken.

- **Only 58% reach maintenance dosing** and 21% never leave the starting dose, in [UK primary care](https://glpwatchdog.org/research/most-people-never-reach-the-dose).
- **Discontinuation runs from 36.9% to 55.8%** depending on drug and formulation, in the same dataset.
- **Half of combination starters stop one drug**, here.

Trials report what happens to people who take the drug, and guidelines assume they do. Neither describes the ordinary experience, and the difference is large. Our piece on [why real-world results differ from trial results](https://glpwatchdog.org/research/who-responds-in-the-real-world) covers the same gap from the other end.

> **Side effects were the stated reason for most discontinuation.** Adding a second drug adds a second side-effect profile rather than averaging them, so a patient asked to take both has two sets of side effects to tolerate instead of one.

## What to take from it

If a combination has been suggested to you, the useful questions are practical ones. What will this cost each month once both are running, which one do we stop first if the side effects are intolerable, and what does the plan look like if only one of them is sustainable?

It is a small, early report (173 participants in the feasibility phase of a larger trial), and it measured something that larger, cleaner trials systematically design out.

## Frequently asked questions

### Does combining an SGLT2 inhibitor with a GLP-1 work?

This trial could not answer that, because too little of the treatment happened. At four months only 53% of the combination group had filled their prescriptions against 84% on a single drug, and half of those who filled later discontinued one.

### Was cost the problem?

Not primarily. The participants were insured and the study team had worked to facilitate uptake. Most discontinuation was attributed to side effects rather than affordability.

### Why would two drugs be so much harder to sustain?

Adding a drug adds its side-effect profile rather than averaging it, so a patient on both has two sets of side effects to tolerate instead of one. The trial did not break the discontinuations down by side effect.

### Does this mean guidelines are wrong?

It means a guideline recommendation and what happens at a pharmacy counter are different things. Trials report outcomes in people who take the drug; this measured how many do.

### What should I ask if a combination is suggested?

What the monthly cost is with both running, which drug is stopped first if side effects become intolerable, and what the plan is if only one turns out to be sustainable.

## References

1. Wexler DJ, Mayberry LS, Nelson LA, et al. Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial. American Heart Journal. 2026. PMID: 41456635. https://pubmed.ncbi.nlm.nih.gov/41456635/

---

Cite as: GLP Watchdog, Ruth Calder, "Why Combination Therapy Fails in Practice", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/why-combination-therapy-fails-in-practice

Canonical HTML page: https://glpwatchdog.org/research/why-combination-therapy-fails-in-practice

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
